These evidences are in accordance with other studies illustrating that PD-L1 expression is governed by oncogenic activation of AKT-mTOR in glioma cells with PTEN deletion, and in lung cancer cells with EGFR or KRAS mutation [121,148,149]. Here, MTOR is linked to central nervous system cancer.